|
Jerry Parrott joined HGS in July 2001 as Vice President Corporate Communications and Public Policy. As Principal of Policy Advocates Inc. from 1995-2001 Mr. Parrott’s clients included HGS Bristol-Myers Squibb Ciba-Geigy Diversa Genentech HealthCare Ventures Hoffmann-La Roche Western Digital Wyeth and other companies. He previously held senior policy and corporate communications management positions with Bristol-Myers Squibb Company (1979-1995) American Hospital Supply Corporation (1976-1979) and Walgreen Company (1973-1976). Mr. Parrott helped launch several important therapeutic products including: Zenapax the first genetically engineered drug to reduce risk of organ rejection; VIDEX the second anti-AIDS drug; Taxol the breakthrough cancer drug; Nuprin the first nonprescription ibuprofen; and Comtrex the nonprescription cough-cold medicine. Mr. Parrott is a member of the Executive Committee and Board of Directors of MdBio and the Technology Council of Maryland. He is a member of the Board of Directors of Maryland Health Care Product Development Corporation the Montgomery County Chamber of Commerce and the Committee for Montgomery and serves as Chairman of the Biotechnology Industry Organization ( BIO) Committee on Outreach and Alliance Development. | 